Release No 17/2010


Changed date for interim financial report for 1st quarter 2010

Copenhagen and Oslo, May 17th, 2010
Affitech A/S has changed the date for publication of the interim financial
report for 1st quarter, 2010 from May 19th 2010 to May 28th 2010.

Affitech A/S's updated financial calendar is as follows:

March 26th 2010: Announcement of financial results for 2009
April 29th 2010: Annual General Meeting
May 28th 2010: Interim financial report for 1st quarter 2010
Aug. 26th 2010: Interim financial report for 2nd quarter 2010
Nov. 18th 2010: Interim financial report for 3rd quarter 2010


--------------------------------------------------------------------------------
| For more information please contact: |
--------------------------------------------------------------------------------
| |
| Affitech A/S: |
| |
| Dr Robert Burns, Chief Executive Officer, |
| Tel # +45 5099 7642 |
| Randi Krogsgaard, Corporate Communications |
| Tel # +45 2320 1001 |
--------------------------------------------------------------------------------
About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company headquartered in Copenhagen, Denmark with R&D facilities in
Oslo, Norway. The company utilizes a range of proprietary antibody technologies
for the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS? (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to cell
surface molecules in situ. Several of the Company's proprietary product
candidates were generated by CBAS?. Further information is available at
www.affitech.com.
Disclaimer
This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
results of the financial condition and operations of Affitech A/S. There are
many factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements
and forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.
No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided herein,
and no claims shall be made by the recipient of this news release by virtue of
the information contained herein.